correct ride wave
 outsourc initi ow
largest clinic cro china integr
platform tigerm benefit rise demand
outsourc trade par a-shar peer despit faster
growth believ stock attract valu
price target impli price-to-earnings project revenu earn
cagr new stock incent program
announc march impli net profit growth least
preliminari result indic net profit growth
stock ralli year sentiment toward sector
especi compani limit polici risk improv result
shown robust growth tigerm trade price-to-earnings vs
averag a-shar peer also higher ep compound-annual-growth-rate
vs peer upsid potenti initi coverag overweight
creat long-term valu establish integr platform tigerm key
advantag clinic cro includ good relationship clinic
institut especi china extens track record high-qual
servic expertis integr long-term relationship larg custom
intern footprint compet global domest peer
rise demand qualiti clinic research servic tigerm benefit
seri reform requir chines compani conduct rigor clinic
trial demonstr efficaci new drug qualiti equival
origin drug gener growth driver includ transit
tradit drug compani innovation-driven upgrad order
rise product expans multi-region clinic trial mrct
integr platform variou tigerm
expand servic area chemistri manufactur control
medic devic biolog analysi data manag enabl
tigerm increas custom sticki provid one-stop servic
lower cost moreov equiti invest grown steadili may
creat posit synergi core busi thu sustain
limit risk risk talent turnov global competit geopolit
up/downsid price target
sh dil curr mn
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
base consensu methodolog
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
top clinic cro expand global rise trend outsourc
top clinic cro expand global rise trend outsourc
deriv base case discount cash flow method use wacc
termin growth rate
earn compound-annual-growth-rate higher revenu cagr base
case higher net margin expans invest incom
earn compound-annual-growth-rate revenu cagr
clinic servic clinical-rel consult minor margin improv
 pace invest incom line expect
earn compound-annual-growth-rate revenu cagr base case due
rise competit net margin eros given labor cost inflat
oper leverag slow lower invest incom
exhibit bull bear case
ampl growth potenti clinic
outsourc servic china
new regul increas clinic trial
demand qualiti cro
largest clinic cro china solid
build integr cro platform
domest trial mrct
robust revenu growth stabl
margin healthi cash flow
brand equiti custom sticki
proven track record
valu chain includ drug devic
deepen penetr pharma
early-phas trial progress phase
fee higher
growth new contract
accret core busi
risk achiev price
geopolit currenc risk
potenti damag reput cost
caus custom claim
impair risk goodwil intang
sale
gener administr expens
profit tax
profit year
net incom attribut common sharehold
cash equival
properti equip net
total liabil equiti
depreci properti plant equip pp
amort intang asset
decreas defer tax asset
increas defer tax liabil
decreas inventori
decreas receiv
increas payabl
net cash oper activ
receiv invest
receiv equiti invest
purchas properti equip
net cash use invest activ
receiv issu stock
receiv borrow
paid dividend profit interest
net cash use financ activ
net increas decreas cash cash equival
cash equival begin
effect foreign exchang rate chang
cash equival end
profit tax
profit tax
made correct invest summari tigerm vs peer section
articl correspond text articl origin publish june
pm gmt republish juli receiv electron copi
origin version public pleas send email
public titl date
initi coverag tigerm overweight rate price target
impli upsid price-to-earnings largest clinic cro china
integr platform believ benefit rise demand
outsourc valuat premium a-shar peer warrant project
revenu earn cagr
strong growth potenti clinic outsourc servic china clinic cro
benefit seri reform china nation medic product administr
nmpa requir compani conduct rigor clinic trial demonstr
efficaci new drug qualiti equival origin gener
lead posit solidifi establish network proven track record end
tigerm involv clinic trial innov drug project
includ novel biolog new chemic drug good relationship
local clinic institut china addit establish servic network
countri region enabl multi-region clinic trial
 drive growth unlock synergi tigerm made variou recent
year macrostat frontag dreamci jietong tairui equiti
invest enabl tigerm establish integr platform provid one-
stop servic enhanc custom sticki
could make us turn less bullish stock could becom less bullish
stock tigerm new contract growth fall short expect competit
lead global domest threaten market share exert margin
pressur meanwhil geopolit tension may hinder tigerm abil serv us
custom could dent growth trajectori also wari uncertainti
regard invest incom goodwil impair
valuat suggest upsid tigerm trade earn roughli par
a-shar cro peer a-shar averag
despit higher ep compound-annual-growth-rate peer also trade
discount iqvia wuxi apptec-h basi global china cro
exhibit valuat comparison a-shar peer
averag select compar exclud tigerm
morgan stanley research estim tigerm wuxi apptec thomson reuter consensu asymch laboratori bgi genom joinn laboratori consensu data porton boji
outsourc potenti pharmaceut compani will trim cost
 product global biopharmaceut industri declin sinc
late addit mani multi-national compani experienc patent
expir blockbust drug combin pipelin drought
gener competit result slow industri growth declin singl digit
doubl digit industri heyday maintain profit drug-mak seek
way ration cost manufactur cope top-lin pressur
outsourc popular way achiev benefit compani tigerm
global cro market divid five segment cell gene therapi
preclin discoveri clinic small-molecul contract manufactur organ
cmo clinic trial small-molecul cmo two largest segment make
total industri revenu total outsourc revenu grew
compound-annual-growth-rate frost sullivan expect growth pick
particular clinic cro expect grow compound-annual-growth-rate
exhibit global cro revenu compound-annual-growth-rate
cell gene therapi cmo/cdmo
exhibit estim cagr outsourc revenu segment
cell gene therapi cmo/cdmo
ampl room clinic outsourc
clinic research servic cover phase formul clinic
develop strategi nda registr pathway formul plan schedul
pre-ind meet regulatori author prepar submit ind
document servic includ monitor clinic trial ensur studi
conduct accord gcp/ich standard data collect process
integr manag servic larg involv coordin manag clinic
center ensur equip employe meet requir protocol
frost sullivan expect market
clinic research servic segment benefit seri reform china
nmpa requir compani conduct rigor clinic trial demonstr
efficaci new drug qualiti equival origin drug gener
exhibit clinic develop servic market see annual growth
global china
exhibit manag servic market china reach
largest clinic cro china solid track record
tigerm includ clinic develop servic site manag organ
oper monitor manag phase i-iv clinic trial outcom research
medic devic trial embed outsourc clinic informat respect
smo servic includ project manag clinic site manag servic
subsidiari offic mainland china oversea offic tigerm
excess full-tim staff global conduct clinic trial
serv custom us eu japan china includ top
global pharma compani top five global tech compani well lead small
medium size pharma compani china
exhibit tigerm largest clinic cro china term revenu us mn
china benefit wave outsourc driven
transit tradit drug compani innovation-driven biotech upgrad
order rise product expans mrct studi tigerm key
advantag includ good relationship clinic institut especi china
extens track record demonstr high-qual servic expertis long-
term relationship larg custom includ global one
increas trial especi innov drug boost demand qualiti clinic cro
sinc juli china healthcar regul introduc polici creat
stringent regulatori environ drug develop highlight
import clinic data acceler review approv process innov
drug enhanc overal qualiti competit gener drug
countri polici combin enhanc regulatori standard support
data recent year led signific increas demand high-qual
studi clinic trial innov drug
end tigerm involv clinic trial innov drug
project includ novel biolog new chemic entiti cover anti-
infect oncolog cardiovascular endocrin therapeut hunan tigerm mainli
provid servic phase clinic trial studi shanghai tigerm involv
phase ii iv trial
exhibit tigerm number class innov drug project
exhibit tigerm custom project
biostatist imag
exhibit tigerm involv
tigerm establish global servic network hong kong taiwan south korea
japan malaysia singapor india australia canada us switzerland
countri region enabl compani conduct multi-region clinic trial
chines compani aim launch new drug outsid china believ demand
mrct increas rapidli tigerm global footprint give advantag
compet global peer well lead local player
us busi provid gmp drug develop clinic manufactur
clinic trial glp bioanalysi intern drug registr servic
one-stop servic platform innov gener drug
australia clinic servic cheaper us ind applic
requir trial start data recogn nmpa fda ema pmda
 incent grant govern cover trial cost
korea japan dreamci improv tigerm footprint asia
strengthen mrct capabl notabl dreamci korean subsidiari
acquir provid clinic cro servic record net profit
incur loss three year
switzerland oper serv start point expand busi
europ provid choic local custom conduct mrct
india subsidiari establish take full advantag india rich resourc
data manag statist analysi relat area
enhanc global servic capabl
clinical-rel consult segment contribut revenu grew
mainli driven smo busi data manag
statist analysi preclin studi medic imag servic record strong
growth respect
frontag complet hong kong ipo may bioanalyt servic
tigerm come mainli frontag main oper us
provid dmpk safeti toxicolog bioanalyt servic china
oper mainli involv studi well bioanalyt servic
frontag revenu reach net profit
us oper includ concord employe contribut total
revenu china oper shanghai suzhou zhengzhou
employe contribut revenu april frontag acquir concord
extend servic rang larg anim test non-glp glp toxicolog
studi support regulatori submiss ind
exhibit frontag revenu net profit us mn
us-safeti toxicolog
exhibit frontag order breakdown new contract sign
us-safeti toxicolog
exhibit frontag order breakdown averag contract size us
us-safeti toxicolog us-bioanalyt
macrostat clinic data manag statist analysi subsidiari mainli
provid servic cover clinic trial manag data manag statist
analysi especi support larg global pharmaceut compani us europ
australia japan china countri intern standard help
reduc cost macrostat built strateg partnership global pharma
biotech compani past key vendor biostatist servic macrostat
jiax tigerm data manag contribut revenu
tigerm second frontag among tigerm subsidiari given
high entri barrier limit number vendor china expect macrostat
record robust growth next year
hangzhou simo smo simo built team clinic
research coordin project manag line manag make
largest recruit team among smo vendor china cover citi
agenc partner experienc team provid on-sit manag clinic
trial investig provid profession support clinic trial sinc
simo work project global assign
juli announc self-inspect clinic trial end
simo clinic project pass inspect success rate
less year
year
cost structur high product
tigerm abl deliv high-qual servic lower cost thank avail
suffici local talent china good oper effici averag cost
colleg post-colleg graduat china less us
addit despit rise labor cost gener china wage new colleg graduat
stay rel stabl tigerm continu expand busi
inexperienc employe repres larger proport total workforc
tigerm revenu net profit per employe highest among a-shar peer
indic better product oper effici
exhibit tigerm revenu cost net profit per employe
build integr clinic servic platform
build integr servic platform tigerm made variou recent
year includ acquisit macrostat frontag dreamci jietong tairui
expand servic offer data manag biolog analysi
medic device-rel cro enabl tigerm integr
busi time manner well rais custom sticki provid
one-stop servic lower cost
stake
clinic data manag analysi
biolog analysi clinic research
clinic research servic pharmaceut biotechnolog medic
devic function food
clinic research servic data manag analysi
cro medic devic
pk data analysi pre-clin trial design
invest variou fund may gener posit synergi
tigerm record invest incom total net profit
leverag current cro platform tigerm made variou equiti invest
mainli innov drug past gener meaning profit
contribut time notabl total financi asset avail sale increas
significantli yoy invest may gener
posit synergi core busi futur thu sustain
limit risk
exhibit tigerm financi asset avail sale rmb mn
net incom
financi asset avail sale
strong growth outlook impli incent program
tigerm announc stock incent program sip march offer
restrict share core technic staff mid-level manag
compani three year total share grant
repres total share outstand offer price set
person entitl offer volum unlock
requir tie net profit may give insight
exercis
net incom
net incom
net incom
exhibit tigerm minimum profit impli sip rmb mn
exhibit tigerm stock compens expens project
robust revenu growth stabl margin healthi oper cash flow
tigerm deliv robust revenu compound-annual-growth-rate net profit compound-annual-growth-rate
stabl gross margin expand net margin roe reach
vs project tigerm record revenu compound-annual-growth-rate
net profit compound-annual-growth-rate moreov tigerm gener healthi oper
cash flow compar net profit preliminari result announc
recent indic strong net profit growth vs
estim
exhibit tigerm revenu margin
despit low visibl cro busi gener tigerm disclos total
contract revenu pend execut backlog revenu exhibit new contract
revenu exhibit increas steadili sinc
recruit retain talent may becom difficult
although larg well-educ local labor pool basic technic
knowledg experienc local talent difficult find retain given tigerm
compet rival expertis boom cro industri continu
educ train essenti complement effect recruit program
major local staff still lack essenti skill experi tigerm
provid on-the-job train new employe competit labor environ
inevit led rise cost experienc scientist technic personnel staff
cost account total cog howev
wage new colleg graduat stay rel stabl tigerm
continu expand busi inexperienc employe repres
increasingli larg proport total workforc keep averag cost stabl
compani data note base year-end headcount
competit global domest cro
tigerm may face rise competit lead global domest term
qualiti servic breadth flexibl servic capac timeli deliveri
servic complianc regulatori standard depth custom relationship
price compet multi-national provid rang servic
complex challeng project tigerm price much cheaper
global peer howev global like iqvia may autonomi local
oper china make key decis might cultur languag
issu employe staff adapt local condit addit smaller
medium size may introduc new servic lower price increas
competit could creat price pressur exampl wuxi apptec lead china-
base cro via acquisit crso austin texa increas effort
clinic research servic includ clinic develop smo servic may
leverag cro experi gain market share establish industri leadership
potenti damag reput cost caus custom claim
tigerm custom could bring claim breach contractu oblig
failur protect intellectu properti servic compani provid complex
often time-sensit materi mistak made compani includ
conduct project process analyz data may caus neg impact
project result improperli report case tigerm may subject
cost repeat project liabil custom potenti damag
reput tigerm top five custom contribut total revenu
maintain good relationship top custom key sustain base
futur cross-sel servic reason relationship big
custom sour impact revenu could signific sudden termin
major contract could lead signific earn volatil
geopolit regulatori risk given rise global presenc
tigerm revenu outsid china
denomin usd thu exchang rate constant risk hedg
decemb rmb depreci usd manag estim net
profit would neg affect total net profit
tigerm also use hedg tool manag fx risk
also note current geopolit environ may unfavor chines
compani exposur us proprietari technolog nation secur
concern us administr may deem collabor chines us
compani riski wall street journal articl june report us senat
marco rubio introduc amend congress defens bill ensur
grant recipi darpa defens advanc research project agenc priorit us
vendor prohibit partner entiti subject control foreign
compani govern restrict could compromis tigerm abil
acquir busi serv us custom encouragingli compar cro
potenti expos proprietari technolog tigerm
focus clinic servic relat consult servic less sensit
drug discoveri term ip protect addit us busi mostli conduct
frontag incorpor cayman island list hong kong
held mostli oversea investor frontag substanti facil oper
us abl offer servic us custom demand
outsourc could slow proport compani outsourc
depend econom intern strategi drug compani could decid conduct
trial in-hous avoid outsourc risk cro industri grow tandem
 spend driven advanc basic scienc ultim bulk
innov come academ institut startup larg compani
point new drug target could come peak trough affect prospect
potenti low earn visibl cro protect custom ident thu
abl disclos granular project work clinic phase
servic provid etc outsid may good visibl contract term
demand bioequival relat servic could weaken
cost per studi charg peak given
significantli increas demand gener drug manufactur requir
howev note number new file receiv centr drug
evalu declin recent month given fewer project left
addit small-siz outsourc vendor start offer price discount
win new contract drastic slowdown demand could affect tigerm
growth trajectori said segment contribut tigerm
revenu segment transfer frontag own listco
exhibit monthli number new file decreas recent
potenti risk goodwil impair
tigerm made number acquisit past record total goodwil
net asset jietong tairui
frontag beiyi renzhi dreamci perform acquir compani
meet expect tigerm may incur impair loss neg affect
earn book impair loss beiyi renzhi
perform meet target notabl risk jietong tairui incur
impair loss futur fail meet target
uncertainti invest incom
invest incom account rise proport net profit past
year although compani focus target could potenti
gener posit synergi core busi invest could uncertain
tigerm portfolio compani fail gener posit return financi
perform may neg affect market expect
iqvia iqv ow cover ricki goldwass largest cro world-wide
busi comparison iqvia formerli quintil im four busi segment
 technolog commerci real-world valu outcom
segment compar tigerm clinic servic segment provid
clinic cro includ trial design strategi develop patient site manag
registr laboratori servic iqvia technolog segment similar tigerm
clinical-rel consult segment render data manag statist support
unlik tigerm iqvia also provid outsourc servic hospit govern
insur addit manufactur
valuat metric iqvia trade earn record revenu
net profit respect morgan stanley
project revenu compound-annual-growth-rate net profit compound-annual-growth-rate
wuxi apptec ow ow largest cro china
busi comparison wuxi apptec largest cro china revenu unlik
tigerm wuxi apptec engag non-clin cro servic servic
special small molecul chemic drug recent acquir pharmapac us-
base clinic cro tap clinic cro tigerm wuxi signific
portion revenu gener oversea
valuat metric wuxi apptec record revenu net incom
respect gener roe due
differ servic portfolio wuxi non-clin focus tigerm clinic
cro tigerm gener slightli higher gross margin oper margin
wuxi net margin higher due gain mostli invest incom
compani data note wuxi oper incom exclud gain/loss
despit compar growth prospect margin tigerm trade discount
wuxi apptec h-share iqvia basi
exhibit price-to-earnings comparison
tigerm trade earn histor averag roughli
par averag price-to-earnings a-shar peer even though expect record
higher ep compound-annual-growth-rate vs peer thomson reuter consensu
tigerm trade a-shar averag
exhibit valuat comparison a-shar peer
averag select compar exclud tigerm
clinic cro pre-clin cro frontag
pre-clin cro innov drug
cro clinic non-clin drug devic health supplement compani
morgan stanley research estim tigerm wuxi apptec thomson reuter consensu asymch laboratori bgi genom joinn laboratori consensu data porton boji
dcf primari valuat methodolog
use cost equiti coe after-tax borrow cost
long-term debt/equ work wacc roughli line
china healthcar coverag space median assum termin growth rate
long-term roe new invest translat equiti
valu stock trade earn earn
histor averag sinc august
equiti
long-term roe new invest
year reach steady-st growth
steady-st borrow cost net tax
conv factor model trade cci
dividend net rep
pv div net rep
long-term rnoa new invest
exhibit wacc assumpt within coverag space
tigerm trade earn histor averag tigerm
trade earn earn histor averag
sinc ipo price target impli earn see ampl room
share price move consid tigerm grown much larger
scale proven track record expect maintain least annual
earn growth
exhibit tigerm share trade histor averag price-to-earnings
stock ralli year compar averag a-shar
cro peer larg driven improv market sentiment polici headwind
overal healthcar sector especi compani limit polici risk like
tigerm releas new three-year stock incent program indic
strong growth outlook success list frontag hong kong
may result continu beat market expect increas weight
china a-shar index believ stock could trade
still histor averag price-to-earnings valuat look attract price-to-earnings
compar averag a-shar peer also higher ep compound-annual-growth-rate
vs peer averag
bull case scenario assum higher earn compound-annual-growth-rate
driven revenu cagr higher base case scenario signific margin
expans higher-than-expect contribut invest
incom yield bull-cas target impli price-to-earnings
bear case scenario assum slower earn compound-annual-growth-rate driven
revenu cagr slower base case scenario margin pressur dilut
volatil contribut invest incom intens competit
global leader yield bear-cas target impli price-to-earnings
invest incom net incom
revenu compound-annual-growth-rate approxim tigerm revenu stood
repres compound-annual-growth-rate owe
compound effect surg cro demand strategi forecast
total revenu grow compound-annual-growth-rate note growth slowdown
mainli due addit cost incur polici self inspect
clinic data implement juli driver deepen penetr
outsourc servic us eu china increas drug innov china
back favor polici demograph shift sign new custom
cross-sel exist custom
revenu growth clinical-rel consult outgrow clinic servic tigerm
two busi segment clinical-rel consult clinic servic contribut
revenu ancillari servic
statist analysi medic imag smo growth jump yoy
fuell smo servic grew data manag statist
analysi preclin studi medic imag servic record revenu growth
project yoy
growth driven data manag statist analysi busi
note due dispos shengtong project contribut
revenu dispos expect revenu growth clinical-
relat consult slow recov
clinic servic tigerm transfer busi entir frontag post
ipo retain right refer custom frontag commiss
allow tigerm focu exclus core clinic trial busi
revenu clinic trial develop registr file servic
yoy growth vs whole segment stage
estim phase trial contribut phase ii trial
contribut trial enter phase gener much higher fee
earlier stage trial project growth
stabl gross margin outlook post dip tigerm margin took hit
cfda nmpa initi self-inspect clinic data qualiti tigerm
project withdrawn three project reject period consequ
clinic trial repeat custom compensatori price gross
margin clinic servic segment declin
dreamci acquir loss-mak time gross margin rebound
stabil clinical-rel consult
clinic servic record gross margin respect
expect gross margin clinic servic stabil current level
sub-contractor revenu zero gross margin decreas
percentag total revenu expect gross margin clinical-rel
consult servic expand everi year loss-mak
shengtong busi dispos fix cost account larg proport
faster grow data manag biometr busi
exhibit tigerm gross margin segment
 ratio declin time oper leverag tigerm record administr
expens exclud
repres revenu respect period
tigerm set new offic zhaoq jiangmen huaian taizhou yancheng
zhanjiang lead temporari hike expens includ
list expens frontag ipo exclud ipo expens would
revenu rest primarili fix natur rent util
tigerm book list expens frontag stock
compens expens new incent program factor oper
leverag expect ratio gradual come
 spend mainli system develop upgrad tigerm spend
account total revenu cost expens
mostli softwar develop upgrad relat data manag
system statist softwar research platform project stabl ratio
 plu percentag total revenu declin
sell expens ratio stabl custom acquisit mostli relationship-
reputation-driven spare much market effort tigerm sell expens
revenu expect stay level
lump one line
lump one line
oper incom tigerm record oper incom net margin
expect grow modest oper
margin expans
exhibit tigerm oper incom margin
larg invest incom gener equiti dispos invest incom
largest non-oper item record
respect net profit mainli come dispos
variou equiti invest made tigerm subsidiari project
invest incom increas par revenu reach
make net incom
 item expect tigerm book interest incom owe
frontag ipo proce minor interest percentag net incom
increas listco interest frontag declin ipo
assum effect tax rate remain stabl next three year similar
level
net incom project net incom outpac revenu slightli come year
net margin expand level note
preliminari result announc recent indic net profit growth yoy
rang includ non-recur profit
vs
net incom
suffici oper cash flow ocf fund capital-expenditure tigerm incur capital-expenditure
repres year
revenu absent major expans plan near term expect capital-expenditure
percentag revenu stay around well cover ocf note
ocf declin yoy mainli due prepay expect
ocf normal come quarter
cash posit tigerm cash plu
financi asset book compar ocf
capital-expenditure capital-expenditure incur frontag
roe expans thank improv margin asset turnov expect tigerm
roe improv
revenu
summari tigerm third-largest cro china revenu largest
clinic cro provid full spectrum cro servic includ clinic servic
clinical-rel consult pharmaceut medic devic compani
offic across mainland china subsidiari oversea tigerm excess
full-tim staff global serv custom
conduct clinic trial list shenzhen chinext board
tigerm
acquisit
acquisit
frontag
acquisit
set offic
malaysia
employe
list
tigerm
employe
set
institut
acquisit
establish
hangzhou
list entiti note dr ye ms cao hold stake combin
act concert assum key manag respons oversea investor
hong kong-shenzhen stock connect hold share tigerm esop
trust hold anoth free-float make total outstand share
exhibit board director supervisor
decemb dr ye ms cao share
pledg respect repres correspond control
share member senior manag share pledg
share own ownership
share pledg share pledg
presid tigerm
year experi medic regulatori affair former medic
director shanghai roch phd oxford univers
govern affair gener manag simo
nearli experi drug research develop registr
clinic year experi busi manag
senior vice presid founder macrostat head biometr
senior vice presid busi develop market
michael senior vice presid daili oper macrostat jiax xinz
year experi manag statist analysi
master medic oncolog washington univers formal
hdb execut vice-president huya bioscienc
year experi financi manag audit project
year experi manag biostatist
one law maker drug medic devic guidanc manag
director china statist associ
revenu breakdown revenu clinical-rel consult
clinic servic respect servic render phase i-iv trial servic
largest total revenu follow frontag preclin servic
data manag smo contribut geograph
revenu gener domest vs oversea respect note contract
oversea subsidiari chines compani revenu would book oversea
exhibit revenu breakdown segment rmb mn
exhibit revenu breakdown major servic
acquisit retent tigerm full-tim employe end
technic staff labor cost amount
make total oper cost
oper
tigerm oper report two busi segment clinical-rel consult
clinic servic clinical-rel consult cover data statist analysi smo
site manag organ preclin test etc clinic servic focus
develop monitor phase i-iv clinic trial ind prepar nda
exhibit tigerm servic offer along drug develop valu chain
compani data note full name abbrevi tabl shown togeth explan
preclin acquisit frontag ownership tigerm
expand servic scope cover preclin stage two laboratori one
pennsylvania us shanghai china two lab oper
standard oper procedur allow method transfer cross-bord data
share file purpos frontag custom includ janssen
beigen blueprint luy chia tak tianq frontag ipo hong kong
stock exchang may
structur optim earli discoveri anim pk trial early-stag in-vitro
bioanalyt studi radiolabel analysi mass balanc studi metabolit
profil frontag dmpk laboratori locat us
quantif chemic drug biolog ligand bind assay analysi liquid
chromatographi mass spectrometri frontag scientist us
scientist shanghai master degre
year relev experi shanghai pennsylvania bioanalyt
laboratori among largest region
toxicolog batch manufactur extract studi impur identif
commerci product releas stabil test like dmpk mainli conduct
us
bioequival studi frontag ipo tigerm transfer entir
servic frontag retain right refer custom commiss
frontag provid one-stop shop gener qce qualiti consist evalu
trial bioanalysi applic file clinic site jointli
manag hospit nmpa us fda ema compliant
clinic trial tigerm core busi deal issu specifi
ich/gcp ethic committe setup patient recruit trial strategi develop
trial design monitor data analysi clinic report composit term
therapeut area tigerm best known tumor autoimmun cardiovascular
infect also cover hematolog endocrinolog rheumat renal
gastroenterolog opthalmolog pediatr till tigerm
involv clinic trial innov drug includ biolog chemic
drug product launch alreadi rest execut
document prepar includ write review product life-cycl plan
promot materi literatur review clinic research protocol case
report train manual patient educ document confer highlight
clinic trial monitor tigerm team experienc project manag
make sure clinic trial conduct accord gcp/ich standard
data manag statist data manag revenu made
tigerm total subsidiari macrostat jiax data
manag tigerm statistician base shanghai jiax
wuhan taiwan korea india us divid three busi
unit data manag divis compil data clinic extern
sourc feed edc electron data collect paper studi
biostatist divis summar interpret clinic data support drug
dataset valid tool support cdisc clinic data interchang standard
consortium implement applic e-submiss
manag independ clinic trial oper busi unit
updat sop conduct audit inspect provid train
pharmacovigil tigerm provid life-cycle safeti manag adr
process post-market surveil tigerm form strateg
partnership launch dual-languag pharmacovigil platform
ad two mnc client
queri crf case report file design clinic data complianc
edc electron data collect in-hous develop clinflash cloud-
base softwar support multipl oper system mobil termin
recogn voic photo addit numer data clinflash use
clinic trial mnc domest custom novemb
tigerm launch clinflash edc substanti reduc data
medic imag fantast bioimag tigerm own subsidiari first
medic imag cro china provid imag protocol develop elig
review diseas progress confirm block read real-tim efficaci
evalu clinic trial standard oncolog packag help
custom shorten clinic trial time substanti end fantast
bioimag form partnership clinic research institut
central lab teddi clinic research lab found teddi
extend lab menu test platform support routin safeti flow cytometri
anatom molecular patholog pk/be companion diagnost clinic
need teddi lab cap ngsp certifi
mrct multi-region clinic trial tigerm set oversea offic countri
region hong kong taiwan south korea japan malaysia singapor india
australia canada us switzerland
australia advantag jurisdict clinic trial requir
ind applic trial data recogn nmpa fda ema pmda
allow fast-track ethic approv importantli cheaper
equival trial us accord frost sullivan estim australian
govern subsid total trial cost
us busi mainli frontag focus preclin analysi gmp-
compliant non-compli process cover small big molecul
korean subsidiari dreamci acquir turn profit
tigerm major hub asia pacif
europ switzerland romania offic arrang mrct europ
indian subsidiari establish take full advantag india rich resourc
data manag statist analysi relat area
enhanc global servic capabl
regulatori file file depart made drug registr divis
medic devic registr divis health food divis cosmet divis
tigerm extens experi applic file china us australia
europ also handl translat process
clinical-rel servic wide rang consult servic clinic support
biostatist audit data manag audit third-parti vendor audit pre-
audit nmpa/fda inspect train design investig crc
manag safeti technician medic writer statistician data manag
gmp consult servic help client bring manufactur site
complianc china gmp us cgmp eu-gmp gmp
smo site manag organ subsidiari hangzhou simo smo
segment made tigerm revenu provid non-med relat
support clinic trial site call centr servic clinic trial coordin
subject recruit manag equip secur manag etc
tigerm smo unit team profession servic hospit
citi
make way medic devic cro jietong tairui consult technic
regulatori aspect clinic evalu medic devic ivd
invest consult tigerm provid strateg market legal financ
govern consult pharma compani lack in-hous resourc
clinic evalu servic drug medic devic clinic evalu allow
drug devic compani pre-gaug product likelihood approv
offici applic exampl tigerm help assess use oversea
clinic data file applic china medic devic tigerm compar
clinic trial result propos devic market product analyz
clinic trial data multipl perspect racial differ trial design
exhibit major subsidiari busi scope
clinic data manag analysi
data manag statist
technolog promot applic
cro medic devic
biolog analysi clinic research
clinic research pharma biotech medic devic food
cro medic devic
compani data morgan stanley research ownership except shanghai shengtong frontag
corpor strategi mission improv custom effici tigerm
enhanc effici chines pharma compani china around
pharmaceut compani gener manufactur littl in-
hous experi tight deadlin limit budget innov
drug mani compani seek help outsourc
function tigerm come aim shorten cycl
enhanc research clinic trial qualiti chines pharma compani
penetr oversea market clinic trial data manag statist
analysi cost rise europ north america reduc cost mnc
prompt move off-shore qualiti data manag
statist analysi servic tigerm hope penetr global cro market
bargain power supplier
supplier equip vendor
often readili avail
threat new entrant
treat substitut
requir substanti time commit late comer
establish clinic trial partner network hire right
new player may abl execut project time
cost-effect manner
tigerm largest clinic cro
altern manag clinic
face competit smaller local
clinic global player
non-clin might look
expand clinic servic
outsourc gain popular vs
in-hous thank cost
bargain power custom
limit vendor could
provid certain servic given high
global pharmaceut sale increas
compound-annual-growth-rate frost sullivan estim growth slow
reach biolog made pie higher
compound-annual-growth-rate biolog segment could surpass take
quarter pharma sale chemic drug deliv steadi growth
meantim reach notabl us china two largest
pharma market repres world-wide revenu respect
better still countri expect report higher growth global
averag due rise public privat invest favor demograph pattern
support polici
exhibit global pharma sale breakdown countri
us patent drug total market market patent
drug made patent drug sale expect frost sullivan
grow compound-annual-growth-rate reach forecast biolog sale
increas compound-annual-growth-rate also
expect us fda drug approv grant small pharma biotech
startup virtual pharma compani
china favor polici demograph fuel growth china pharma sale
stood forecast grow compound-annual-growth-rate
support polici demograph shift rise dispos incom
increas health awar key driver histor china drug market
domin gener import patent drug patent drug
market share revenu much lower volum share sinc govern
roll initi acceler innov drug approv enhanc clinic trial
standard streamlin gener portfolio consequ expect patent
drug grow much higher rate annual
exhibit china pharma market chemic drug biolog vs
cro deriv global pharmaceut market
global drug expenditur consum drug revenu
despit drastic capit time commit product declin sinc
late us exampl innov drug take year
earli discoveri market overal success rate
in-hous depart challeng increasingli difficult target
lead identif higher time sensit budget constraint tap new
research area cro emerg altern ration cost smooth
revenu volatil mnc meantim biotech start-up virtual compani
lack in-hous capabl manag entir drug develop process
outsourc step
china cro took post decad heavili
orient toward gener drug servic mark turn point one
hand new gener qce qualif consist evalu requir led
signific increas demand test outsourc tigerm revenu
grew yoy hand seri polici roll
encourag drug innov improv clinic data integr tradit pharma
compani lack relev experi know-how cro becom popular
exhibit play role stage along drug develop valu chain
research
market
cro supremaci vs in-hous offer distinct value-add larg pharma
compani start-up thank special talent pool capac
ration central risk control
maxim util laboratori clinic trial site
comparison in-hous face risk idl capac case pipelin cliff
expertis allow pharma compani test water term new
method cutting-edg research arena make full-scal invest
valuabl even larg mnc face increas top-lin pressur
needless say biotech start-up engag optim clinic
strategi handl execut
hospit intermediari hospit china qualifi clinic
trial match project right hospit moreov expans
mrct call coordin global scale
 cycl acceler timeli increas import drug target
popular pathway biosimilar qualiti cro strong data capabl
extens experi achiev faster deliveri tigerm estim shorten
project timelin approxim year custom outsourc phase
ii iii trial one go compani also experienc regulatori
affair tigerm success file two drug default permiss
clinic trial eight total drug approv
risk ration pool project togeth risk volatil success rate
reduc
concern associ cro transpar data integr confidenti
major concern outsourc vendor cfda self-inspect requir
caus thousand applic withdrawn reject leav dent
margin said believ custom will pay premium
good reput strict qualiti control proven success rate
develop market like us europ spend alreadi
outsourc frost sullivan estim reach china cro
penetr ratio lag behind expect catch
expect reach compound-annual-growth-rate
exhibit penetr ratio outsourc
china cro wit compound-annual-growth-rate next five year china one
attract market compound growth overal pharmaceut revenu
increas deepen penetr cro size
expect reach repres compound-annual-growth-rate translat
global share vs today us cro market made
global cro countri share frost sullivan see grow compound-annual-growth-rate
polici tailwind china
state council issu opinion reform review approv
drug medic devic perman chang landscap
china overarch goal acceler innov drug launch enhanc
stringent clinic trial data requir call qualiti clinic trial servic
self-inspect urg cfda new drug applic withdrawn
reject tigerm project withdrawn three reject
period tighten requir clinic data pose temporari setback
mani project redon discount price left dent
industri gross margin nevertheless tighten requir compel cro
industri better self-regul qualiti control encourag develop
medium long term
govern target cro capac new biolog launch per year
five-year list biolog drug innov top prioriti play critic
role biolog develop due complic trial develop
manufactur monitor data process compar small molecul
chemic drug june three author jointli issu notic
construct biolog cro platform emphas import
biolog innov govern target enough industry-wid capac
support develop biolog launch per year
still complet albeit intensifi competit consist
evalu opinion issu gener drug requir complet qce
qualiti consist evalu failur preclud drug re-
registr due sheer amount gener affect gener
commerci product pass may pharma compani lack histor
data in-hous thu volum outsourc project like stay high
near term howev seen sign price cut recent light fewer project
left intensifi competit moreov price cut central
procur drug turn drastic market expect exert
pressur pharma compani ration futur spend segment
contribut tigerm revenu
mah scheme incentiv small innov provinc select
mah market author holder pilot program mah system drug
research institut hold market author without invest
manufactur facil small innov independ research centr key
beneficiari often heavili reliant drug develop process
mah pilot program extend novemb might
set key polici implic cro
exhibit polici tailwind spur demand qualiti cro servic china
implic cro
twelfth five-year
promot innov pharmaceut industri plan
intern center green environ
set tone top encourag innov particularli
biolog drug cro provid critic support
announc self-inspect
verif drug clinic
trial data registr
improv clinic data qualiti standard solv
backlog problem clinic applic
setback cro short term call qualiti
clinic monitor data manag servic
opinion reform review
approv system drug
guid document promot drug medic
devic innov acceler review process
overarch document ignit interest drug
innov turn benefit cro
improv standard gener drug
spike demand dmpk test
notic commenc mah trial
select provinc market author
separ product author
opinion strengthen reform
drug medic devic
review approv
speed process applic approv
product releas market encourag
innov drug medic equip enhanc
manag life cycl drug medic
incentiv small local innov often lack in-
hous resourc clinic trial manufactur
call qualiti servic support drug medic
notic construct
biolog cro platform
support commerci innov
drug improv product scale effici
direct recognit role cro biolog
develop also set capac target whole
improv medic insur plan promot
healthi develop medic industri improv
drug qualiti standard reduc price etc
demand test
cro fragment industri largest global account market
share revenu accord frost sullivan carolina-bas iqvia formerli
quintil im largest cro world-wide
china eight largest account revenu share wuxi
apptec biggest player differ tigerm wuxi apptec engag
non-clin arena cro servic special small
exhibit domest global cro
invest
beij sihui acquir ireland
manag analysi registr
drug medic equip
cro pharma medic devic health
clinic trial research chemic drug biolog
tcm medic equip pharmacolog test
investig compound train drug
acquir becom
part global network
global cro strong presenc china
acquir wuxi apptec
dual list hkex shanghai stock
exchang
drug manufactur cell gene therapi
drug servic includ synthet medicin
drug safeti assess radiochemistri clinic
develop includ applic
north carolina us
offic
countri
offic shanghai provid
servic clinic trial research
multicent research lab
full rang clinic servic data manag
statist analysi servic consult pharma
compani public health insur hospit
us global site
employe
north carolina us
offic
boston us
countri
enter china set
trial center shanghai
clinic trial monitor manag drug
first offic beij clinic
research center vaccin
jiangsu multicent lab
global drug registr
site beij shanghai chengdu
contract research medic commun
clinic trial partner network hospit china qualifi
clinic trial take signific time capit commit new entrant build
relationship institut
acquisit prolong shortag talent includ scientist
statistician regulatori affair specialist experienc project manag tigerm
full-tim employe plan expand
offer well-articul stock incent program help retain talent vs
high initi invest lab clinic trial site equip technolog necessari
high switch cost/reputation-driven client put high relianc reput
select vendor given high cost associ project failur vendor
switch tigerm serv custom conduct clinic
complianc clinic trial china must follow mrct must follow ich-
standard take extens resourc experienc personnel ensur complianc
tigerm facil pass dozen inspect nmpa us fda ema
clinic cro second-largest subset cro servic
cro industri divid five segment cell gene therapi
preclin discoveri clinic small-molecul contract manufactur organ
clinic trial second largest compon make total cro revenu
frost sullivan expect clinic cro increas compound-annual-growth-rate
reach global clinic cro servic cover ind prepar phase iv
clinic trial design monitor data manag statist analysi nda file
post-market surveil ancillari servic
exhibit estim compound-annual-growth-rate outsourc revenu segment
cell gene therapi cmo/cdmo
exhibit global cro revenu compound-annual-growth-rate
cell gene therapi cmo/cdmo
exhibit servic clinic cro
drug random code
crf trial data input
tabl list key clinic cro servic includ
clinic trial servic span phase trial import servic
offer clinic design clinic trial togeth custom
patient criteria dosag escal method placebo choic etc clinic cro
take initi recruit patient set ethic committe select trial
hospit build qualiti control system monitor trial progress summar trial
result shown expect clinic servic segment china grow
repres compound-annual-growth-rate
smo smo provid non-medical-rel support clinic trial call
centr servic clinic trial coordin subject recruit manag
equip secur manag market size
forecast reach compound-annual-growth-rate
clinic trial data manag analysi trial design data manag
team come construct custom databas base trial purpos
input patient crf case report form trial process record
databas verifi preliminari dataset filter arriv final dataset
submit review author
clinic trial statist analysi consist design random method
choic singl arm/multipl arm hypothesi formul statist analysi
tool use drug random medic code compos statist
report present file purpos
registr hire team regulatori expert prepar document file
ind nda provid translat servic need
valuat methodolog risk
dcf-base price target assum wacc termin
risk achiev price target project cancel strateg deal lead price
pressur margin deterior im synergi fail materi client
servic disrupt result im merger integr
price target deriv discount cash flow wacc termin
risk achiev price target talent turnov margin pressur us busi global
competit ip protect reput risk geopolit risk
deriv h-share price target a-shar price target assum
hk rmb exchang rate a-over-h price premium median daili
risk achiev price target talent turnov margin pressur us busi global
competit ip protect reput risk geopolit risk
